Revolution Medicines (RVMD) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, to elironrasib, the company’s RAS(ON) G12C-selective inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback